TISSIUM Receives Funding From the Crohn's & Colitis Foundation to Improve IBD Patient Outcomes

PARIS--(BUSINESS WIRE)-- #biomorphic--TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today that they have received funding from the Crohn's & Colitis Foundation's IBD Ventures, a funding mechanism intended to accelerate the discovery and development of novel research-based products with the potential to alleviate suffering caused by inflammatory bowel disease (IBD). The funding will support TISSIUM’s development of solutions that ad